Prognostic impact of pre- and postoperative tumor markers in patients with intrahepatic cholangiocarcinoma
© 2023. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd..
PURPOSE: The present study assessed the impact of pre- and postoperative tumor markers on the survival of patients with intrahepatic cholangiocarcinoma.
METHODS: Medical records of 73 patients with intrahepatic cholangiocarcinoma were reviewed retrospectively. The pre- and postoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels were assessed. Patient characteristics, clinicopathological factors, and prognostic factors were analyzed.
RESULTS: The median recurrence-free survival and overall survival were 30.0 and 90.9 months, respectively. A multivariate survival analysis revealed that elevated postoperative carbohydrate antigen 19-9 (p = 0.023) was the only independent poor prognostic factor. The median overall survival of patients with normal and elevated postoperative carbohydrate antigen 19-9 levels was 101.4 and 15.7 months (p < 0.001), respectively. Multivariate logistic regression identified elevated preoperative carbohydrate antigen 19-9 as an independent preoperative risk factor for elevated postoperative carbohydrate antigen 19-9. The optimal cutoff value of preoperative carbohydrate antigen 19-9 for predicting elevated postoperative carbohydrate antigen 19-9 was 40 U/mL, with a sensitivity and specificity of 92% and 87%, respectively (area under curve = 0.915).
CONCLUSIONS: Elevated postoperative carbohydrate antigen 19-9 was an independent poor prognostic factor. Preoperative predictors, such as elevated preoperative carbohydrate antigen 19-9, may indicate the need for neoadjuvant therapies to improve the survival.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Surgery today - 54(2024), 2 vom: 21. Jan., Seite 177-185 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Okada, Kenjiro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers, Tumor |
|---|
| Anmerkungen: |
Date Completed 23.01.2024 Date Revised 23.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00595-023-02715-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358416388 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358416388 | ||
| 003 | DE-627 | ||
| 005 | 20240123231845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00595-023-02715-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1268.xml |
| 035 | |a (DE-627)NLM358416388 | ||
| 035 | |a (NLM)37340141 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Okada, Kenjiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic impact of pre- and postoperative tumor markers in patients with intrahepatic cholangiocarcinoma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.01.2024 | ||
| 500 | |a Date Revised 23.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd. | ||
| 520 | |a PURPOSE: The present study assessed the impact of pre- and postoperative tumor markers on the survival of patients with intrahepatic cholangiocarcinoma | ||
| 520 | |a METHODS: Medical records of 73 patients with intrahepatic cholangiocarcinoma were reviewed retrospectively. The pre- and postoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels were assessed. Patient characteristics, clinicopathological factors, and prognostic factors were analyzed | ||
| 520 | |a RESULTS: The median recurrence-free survival and overall survival were 30.0 and 90.9 months, respectively. A multivariate survival analysis revealed that elevated postoperative carbohydrate antigen 19-9 (p = 0.023) was the only independent poor prognostic factor. The median overall survival of patients with normal and elevated postoperative carbohydrate antigen 19-9 levels was 101.4 and 15.7 months (p < 0.001), respectively. Multivariate logistic regression identified elevated preoperative carbohydrate antigen 19-9 as an independent preoperative risk factor for elevated postoperative carbohydrate antigen 19-9. The optimal cutoff value of preoperative carbohydrate antigen 19-9 for predicting elevated postoperative carbohydrate antigen 19-9 was 40 U/mL, with a sensitivity and specificity of 92% and 87%, respectively (area under curve = 0.915) | ||
| 520 | |a CONCLUSIONS: Elevated postoperative carbohydrate antigen 19-9 was an independent poor prognostic factor. Preoperative predictors, such as elevated preoperative carbohydrate antigen 19-9, may indicate the need for neoadjuvant therapies to improve the survival | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Carbohydrate antigen 19-9 | |
| 650 | 4 | |a Carcinoembryonic antigen | |
| 650 | 4 | |a Intrahepatic cholangiocarcinoma | |
| 650 | 4 | |a Neoadjuvant therapy | |
| 650 | 4 | |a Postoperative | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a CA-19-9 Antigen |2 NLM | |
| 700 | 1 | |a Kobayashi, Tsuyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kuroda, Shintaro |e verfasserin |4 aut | |
| 700 | 1 | |a Mashima, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Hashimoto, Masakazu |e verfasserin |4 aut | |
| 700 | 1 | |a Tahara, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ohira, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Uemura, Kenichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Shinya |e verfasserin |4 aut | |
| 700 | 1 | |a Ohdan, Hideki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Surgery today |d 1997 |g 54(2024), 2 vom: 21. Jan., Seite 177-185 |w (DE-627)NLM012623938 |x 1436-2813 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2024 |g number:2 |g day:21 |g month:01 |g pages:177-185 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00595-023-02715-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2024 |e 2 |b 21 |c 01 |h 177-185 | ||